Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Sep 5;26(9):1683-1684.
doi: 10.1093/neuonc/noae118.

Proteasome inhibition for glioblastoma: Lessons learned and new opportunities

S John Liu  1 , David R Raleigh  2 , John F de Groot  3
Affiliations
Editorial

Proteasome inhibition for glioblastoma: Lessons learned and new opportunities

S John Liu et al. Neuro Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

John de Groot has received honoraria or consulting fees from Kintara Pharmaceuticals, Kazia, MundiPharma, Insightec, Monteris, Carthera, Samus, Sapience, DSP Pharma, Telix, Servier, Alpha Pharmaceuticals, Nerviano and CapitalOne and serves on the DSMB for Chimerix and VBI. The remaining authors have no conflicts of interest.

Comment on

  • Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial.
    Roth P, Gorlia T, Reijneveld JC, de Vos F, Idbaih A, Frenel JS, Le Rhun E, Sepulveda JM, Perry J, Masucci GL, Freres P, Hirte H, Seidel C, Walenkamp A, Lukacova S, Meijnders P, Blais A, Ducray F, Verschaeve V, Nicholas G, Balana C, Bota DA, Preusser M, Nuyens S, Dhermain F, van den Bent M, O'Callaghan CJ, Vanlancker M, Mason W, Weller M. Roth P, et al. Neuro Oncol. 2024 Sep 5;26(9):1670-1682. doi: 10.1093/neuonc/noae053. Neuro Oncol. 2024. PMID: 38502052 Free PMC article. Clinical Trial.

References

    1. Stupp R, Mason WP, van den Bent MJ, et al. ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. - PubMed
    1. Mandel JJ, Yust-Katz S, Patel AJ, et al. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol. 2018;20(1):113–122. - PMC - PubMed
    1. Roth P, Gorlia T, Reijneveld JC, et al. ; EORTC Brain Tumor Group and the Canadian Cancer Trials Group. Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial. Neuro Oncol. 2024;26(9):1670–1682. - PMC - PubMed
    1. Richardson PG, Sonneveld P, Schuster MW, et al. ; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–2498. - PubMed
    1. Boccellato C, Kolbe E, Peters N, et al. Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist. Cell Death Dis. 2021;12(7):647. - PMC - PubMed

MeSH terms

Substances